BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 27191652)

  • 1. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
    Zheng H; Liu X; Zhang J; Rice SJ; Wagman M; Kong Y; Zhu L; Zhu J; Joshi M; Belani CP
    Oncotarget; 2016 Aug; 7(35):56233-56240. PubMed ID: 27191652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Incorvaia L; Fanale D; Badalamenti G; Barraco N; Bono M; Corsini LR; Galvano A; Gristina V; Listì A; Vieni S; Gori S; Bazan V; Russo A
    Adv Ther; 2019 Oct; 36(10):2600-2617. PubMed ID: 31432460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer.
    Shibaki R; Murakami S; Shinno Y; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Yamamoto N; Ohe Y
    Cancer Immunol Immunother; 2020 Jul; 69(7):1229-1236. PubMed ID: 32152703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.
    Boffa DJ; Graf RP; Salazar MC; Hoag J; Lu D; Krupa R; Louw J; Dugan L; Wang Y; Landers M; Suraneni M; Greene SB; Magaña M; Makani S; Bazhenova L; Dittamore RV; Nieva J
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1139-1145. PubMed ID: 28446544
    [No Abstract]   [Full Text] [Related]  

  • 5. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.
    Zhang F; Bai H; Gao R; Fei K; Duan J; Zhang Z; Wang J; Hu X
    Cancer Immunol Immunother; 2020 Dec; 69(12):2599-2611. PubMed ID: 32591861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression levels should be considered when identifying risk factors in NSCLC patients treated with nivolumab.
    Li P; Che G
    Cancer Immunol Immunother; 2020 Mar; 69(3):489. PubMed ID: 31807877
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
    Chargin A; Morgan R; Sundram U; Shults K; Tsay EL; Ratti N; Patterson BK
    Cancer Immunol Immunother; 2016 Nov; 65(11):1317-1323. PubMed ID: 27565980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating leukocyte-platelet complexes as a predictive biomarker for the development of immune-related adverse events in advanced non-small cell lung cancer patients receiving anti-PD-(L)1 blocking agents.
    Zamora C; Riudavets M; Anguera G; Alserawan L; Sullivan I; Barba A; Serra J; Ortiz MA; Gallardo P; Perea L; Gavira J; Barnadas A; Majem M; Vidal S
    Cancer Immunol Immunother; 2021 Jun; 70(6):1691-1704. PubMed ID: 33388994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer.
    Li YD; Lamano JB; Lamano JB; Quaggin-Smith J; Veliceasa D; Kaur G; Biyashev D; Unruh D; Bloch O
    Cancer Immunol Immunother; 2019 Sep; 68(9):1501-1513. PubMed ID: 31489465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients.
    Juliá EP; Mandó P; Rizzo MM; Cueto GR; Tsou F; Luca R; Pupareli C; Bravo AI; Astorino W; Mordoh J; Martín C; Levy EM
    Cancer Immunol Immunother; 2019 Oct; 68(10):1585-1596. PubMed ID: 31515670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.
    MacFarlane AW; Yeung HM; Alpaugh RK; Dulaimi E; Engstrom PF; Dasari A; Campbell KS; Vijayvergia N
    Cancer Immunol Immunother; 2021 Jul; 70(7):1893-1906. PubMed ID: 33398390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Missing prognostic value of soluble PD-1, PD-L1 and PD-L2 in lung cancer patients undergoing chemotherapy - A CEPAC-TDM biomarker substudy.
    Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S355-S367. PubMed ID: 38277316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non-small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics.
    Hummelink K; Tissier R; Bosch LJW; Krijgsman O; van den Heuvel MM; Theelen WSME; Damotte D; Goldwasser F; Leroy K; Smit EF; Meijer GA; Thommen DS; Monkhorst K
    Clin Cancer Res; 2024 Feb; 30(4):814-823. PubMed ID: 38088895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 as a predictive factor for non-small-cell lung cancer prognosis.
    Chen L; Zhu XZ; Zhao SJ; Yang QW
    Lancet Oncol; 2024 Jun; 25(6):e233. PubMed ID: 38821094
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-1 expression on the surface of peripheral blood CD4
    Zhang W; Bai JF; Zuo MX; Cao XX; Chen M; Zhang Y; Han X; Zhong DR; Zhou DB
    Cancer Med; 2016 Nov; 5(11):3077-3084. PubMed ID: 27709793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
    Laza-Briviesca R; Cruz-Bermúdez A; Nadal E; Insa A; García-Campelo MDR; Huidobro G; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Massuti B; Casarrubios M; Sierra-Rodero B; Tarín C; García-Grande A; Haymaker C; Wistuba II; Romero A; Franco F; Provencio M
    Clin Transl Med; 2021 Jul; 11(7):e491. PubMed ID: 34323406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Novel Low-Density Neutrophil Markers Through Unbiased High-Dimensional Flow Cytometry Screening in Non-Small Cell Lung Cancer Patients.
    Valadez-Cosmes P; Maitz K; Kindler O; Raftopoulou S; Kienzl M; Santiso A; Mihalic ZN; Brcic L; Lindenmann J; Fediuk M; Pichler M; Schicho R; Houghton AM; Heinemann A; Kargl J
    Front Immunol; 2021; 12():703846. PubMed ID: 34484199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PD-L1 for non-small-cell lung cancer.
    Feld E; Horn L
    Immunotherapy; 2016 Jun; 8(6):747-58. PubMed ID: 27197542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino L; Botti G; Lorigan P; Masucci GV; Hipp JD; Horak CE; Melero I; Ascierto PA
    Drugs; 2016 Jun; 76(9):925-45. PubMed ID: 27229745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
    Cree IA; Booton R; Cane P; Gosney J; Ibrahim M; Kerr K; Lal R; Lewanski C; Navani N; Nicholson AG; Nicolson M; Summers Y
    Histopathology; 2016 Aug; 69(2):177-86. PubMed ID: 27196116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.